The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 3 April 2007, www.theannals.com, DOI 10.1345/aph.1H556.
 The Annals of Pharmacotherapy: Vol. 41, No. 5, pp. 851-856. DOI 10.1345/aph.1H556
© 2007 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fohey, K. D
Right arrow Articles by Nelson, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fohey, K. D
Right arrow Articles by Nelson, L. A.

DRUG INFORMATION ROUNDS

The Role of Selegiline in the Treatment of Negative Symptoms Associated with Schizophrenia

Krista D Fohey, BS

PharmD Student, School of Pharmacy, University of Missouri–Kansas City, Kansas City, MO

Robin Hieber, PharmD

Clinical Pharmacist, Western Missouri Mental Health Center, Kansas City

Leigh Anne Nelson, PharmD BCPP

Assistant Professor, School of Pharmacy, University of Missouri–Kansas City

Reprints: Dr. Nelson, Division of Pharmacy Practice, School of Pharmacy, University of Missouri–Kansas City, M3-C19 Medical School Building, 2411 Holmes St., Kansas City, MO 64108, fax 816/512-7478, nelsonla{at}umkc.edu

OBJECTIVE: To evaluate the role of selegiline in the treatment of negative symptoms associated with schizophrenia.

DATA SOURCES: MEDLINE (1966–January 2007) and PsychINFO (1967–January 2007) were searched, using the terms schizophrenia, negative symptoms, and selegiline. A bibliographic search was conducted, as well.

STUDY SELECTION AND DATA EXTRACTION: All English-language articles identified from the search were evaluated. All primary literature was included in the review.

DATA SYNTHESIS: Based on its dopamine-enhancing property, selegiline has been studied as augmentation to antipsychotic therapy for the treatment of negative symptoms associated with schizophrenia. The efficacy of low-dose oral selegiline for the treatment of negative symptoms has been evaluated in 1 case report, 2 open-label trials, and 2 controlled trials. The case report and both open-label trials report improvement of negative symptoms associated with low-dose oral selegiline. In 1 of the controlled trials, selegiline showed no difference in effect from that of placebo. These data are limited by small sample sizes. The largest controlled trial demonstrated a statistically significant difference between selegiline and placebo; however, the clinical significance is questionable, given that patients treated with selegiline were still experiencing marked negative symptoms at study completion. No comparative studies evaluating low-dose oral selegiline versus other augmentative treatment options for negative symptoms associated with schizophrenia exist at this time.

CONCLUSIONS: Given the limitations of current literature, low-dose oral selegiline cannot be recommended for treatment of negative symptoms associated with schizophrenia. Additional controlled trials are needed to better delineate whether there is a role for selegiline in decreasing the burden of negative symptoms associated with schizophrenia.

Key Words: negative symptoms, schizophrenia, selegiline

Published Online, April 3, 2007. www.theannals.com, DOI 10.1345/aph.1H556




homecopy help contact us subscription past issues search current issue
Copyright © 2007 by Harvey Whitney Books Company.